Oncolytic Virus Therapies Market Size, Share, Growth and Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Oncolytic Virus Therapies Market Size Analysis

Global Oncolytic Virus Therapies Market Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value

North America Market Analysis

Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value
U.S.
1. By Commercialized Therapies
  1. Introduction
    1. Commercialized Therapies By Value
  2. Imlygic
    1. By Value
  3. Oncorine
    1. By Value
  4. RIGVIR
    1. By Value
2. By Pipeline Therapies
  1. Introduction
    1. Pipeline Therapies By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
3. By Type of Virus
  1. Introduction
    1. Type of Virus By Value
  2. Genetically Engineered Oncolytic Virus
    1. By Value
    2. Herpes Simplex Virus (HSV)
      1. Herpes Simplex Virus (HSV) By Value
    3. Adenovirus
      1. Adenovirus By Value
    4. Vaccinia Virus
      1. Vaccinia Virus By Value
    5. Oncolytic Wild-Type Virus
      1. Oncolytic Wild-Type Virus By Value
  3. Reovirus (Respiratory Enteric Orphan Virus)
    1. By Value
    2. Newcastle Disease Virus (NDV)
      1. Newcastle Disease Virus (NDV) By Value
    3. Vesicolar Stomatitis Virus (VSV)
      1. Vesicolar Stomatitis Virus (VSV) By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Solid Tumor
    1. By Value
    2. Breast Cancer
      1. Breast Cancer By Value
    3. Prostate Cancer
      1. Prostate Cancer By Value
    4. Lung Cancer
      1. Lung Cancer By Value
    5. Glioblastoma
      1. Glioblastoma By Value
    6. Melanoma
      1. Melanoma By Value
    7. Other Applications
      1. Other Applications By Value
  3. Hematological Malignancies
    1. By Value
    2. Lymphoma
      1. Lymphoma By Value
    3. Leukemia
      1. Leukemia By Value
    4. Myeloma
      1. Myeloma By Value
Canada

Europe Market Analysis

Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value
U.K.
1. By Commercialized Therapies
  1. Introduction
    1. Commercialized Therapies By Value
  2. Imlygic
    1. By Value
  3. Oncorine
    1. By Value
  4. RIGVIR
    1. By Value
2. By Pipeline Therapies
  1. Introduction
    1. Pipeline Therapies By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
3. By Type of Virus
  1. Introduction
    1. Type of Virus By Value
  2. Genetically Engineered Oncolytic Virus
    1. By Value
    2. Herpes Simplex Virus (HSV)
      1. Herpes Simplex Virus (HSV) By Value
    3. Adenovirus
      1. Adenovirus By Value
    4. Vaccinia Virus
      1. Vaccinia Virus By Value
    5. Oncolytic Wild-Type Virus
      1. Oncolytic Wild-Type Virus By Value
  3. Reovirus (Respiratory Enteric Orphan Virus)
    1. By Value
    2. Newcastle Disease Virus (NDV)
      1. Newcastle Disease Virus (NDV) By Value
    3. Vesicolar Stomatitis Virus (VSV)
      1. Vesicolar Stomatitis Virus (VSV) By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Solid Tumor
    1. By Value
    2. Breast Cancer
      1. Breast Cancer By Value
    3. Prostate Cancer
      1. Prostate Cancer By Value
    4. Lung Cancer
      1. Lung Cancer By Value
    5. Glioblastoma
      1. Glioblastoma By Value
    6. Melanoma
      1. Melanoma By Value
    7. Other Applications
      1. Other Applications By Value
  3. Hematological Malignancies
    1. By Value
    2. Lymphoma
      1. Lymphoma By Value
    3. Leukemia
      1. Leukemia By Value
    4. Myeloma
      1. Myeloma By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value
China
1. By Commercialized Therapies
  1. Introduction
    1. Commercialized Therapies By Value
  2. Imlygic
    1. By Value
  3. Oncorine
    1. By Value
  4. RIGVIR
    1. By Value
2. By Pipeline Therapies
  1. Introduction
    1. Pipeline Therapies By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
3. By Type of Virus
  1. Introduction
    1. Type of Virus By Value
  2. Genetically Engineered Oncolytic Virus
    1. By Value
    2. Herpes Simplex Virus (HSV)
      1. Herpes Simplex Virus (HSV) By Value
    3. Adenovirus
      1. Adenovirus By Value
    4. Vaccinia Virus
      1. Vaccinia Virus By Value
    5. Oncolytic Wild-Type Virus
      1. Oncolytic Wild-Type Virus By Value
  3. Reovirus (Respiratory Enteric Orphan Virus)
    1. By Value
    2. Newcastle Disease Virus (NDV)
      1. Newcastle Disease Virus (NDV) By Value
    3. Vesicolar Stomatitis Virus (VSV)
      1. Vesicolar Stomatitis Virus (VSV) By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Solid Tumor
    1. By Value
    2. Breast Cancer
      1. Breast Cancer By Value
    3. Prostate Cancer
      1. Prostate Cancer By Value
    4. Lung Cancer
      1. Lung Cancer By Value
    5. Glioblastoma
      1. Glioblastoma By Value
    6. Melanoma
      1. Melanoma By Value
    7. Other Applications
      1. Other Applications By Value
  3. Hematological Malignancies
    1. By Value
    2. Lymphoma
      1. Lymphoma By Value
    3. Leukemia
      1. Leukemia By Value
    4. Myeloma
      1. Myeloma By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value
UAE
1. By Commercialized Therapies
  1. Introduction
    1. Commercialized Therapies By Value
  2. Imlygic
    1. By Value
  3. Oncorine
    1. By Value
  4. RIGVIR
    1. By Value
2. By Pipeline Therapies
  1. Introduction
    1. Pipeline Therapies By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
3. By Type of Virus
  1. Introduction
    1. Type of Virus By Value
  2. Genetically Engineered Oncolytic Virus
    1. By Value
    2. Herpes Simplex Virus (HSV)
      1. Herpes Simplex Virus (HSV) By Value
    3. Adenovirus
      1. Adenovirus By Value
    4. Vaccinia Virus
      1. Vaccinia Virus By Value
    5. Oncolytic Wild-Type Virus
      1. Oncolytic Wild-Type Virus By Value
  3. Reovirus (Respiratory Enteric Orphan Virus)
    1. By Value
    2. Newcastle Disease Virus (NDV)
      1. Newcastle Disease Virus (NDV) By Value
    3. Vesicolar Stomatitis Virus (VSV)
      1. Vesicolar Stomatitis Virus (VSV) By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Solid Tumor
    1. By Value
    2. Breast Cancer
      1. Breast Cancer By Value
    3. Prostate Cancer
      1. Prostate Cancer By Value
    4. Lung Cancer
      1. Lung Cancer By Value
    5. Glioblastoma
      1. Glioblastoma By Value
    6. Melanoma
      1. Melanoma By Value
    7. Other Applications
      1. Other Applications By Value
  3. Hematological Malignancies
    1. By Value
    2. Lymphoma
      1. Lymphoma By Value
    3. Leukemia
      1. Leukemia By Value
    4. Myeloma
      1. Myeloma By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Commercialized Therapies
1. Introduction
  1. Commercialized Therapies By Value
2. Imlygic
  1. By Value
3. Oncorine
  1. By Value
4. RIGVIR
  1. By Value
By Pipeline Therapies
1. Introduction
  1. Pipeline Therapies By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Type of Virus
1. Introduction
  1. Type of Virus By Value
2. Genetically Engineered Oncolytic Virus
  1. By Value
  2. Herpes Simplex Virus (HSV)
    1. Herpes Simplex Virus (HSV) By Value
  3. Adenovirus
    1. Adenovirus By Value
  4. Vaccinia Virus
    1. Vaccinia Virus By Value
  5. Oncolytic Wild-Type Virus
    1. Oncolytic Wild-Type Virus By Value
3. Reovirus (Respiratory Enteric Orphan Virus)
  1. By Value
  2. Newcastle Disease Virus (NDV)
    1. Newcastle Disease Virus (NDV) By Value
  3. Vesicolar Stomatitis Virus (VSV)
    1. Vesicolar Stomatitis Virus (VSV) By Value
By Application
1. Introduction
  1. Application By Value
2. Solid Tumor
  1. By Value
  2. Breast Cancer
    1. Breast Cancer By Value
  3. Prostate Cancer
    1. Prostate Cancer By Value
  4. Lung Cancer
    1. Lung Cancer By Value
  5. Glioblastoma
    1. Glioblastoma By Value
  6. Melanoma
    1. Melanoma By Value
  7. Other Applications
    1. Other Applications By Value
3. Hematological Malignancies
  1. By Value
  2. Lymphoma
    1. Lymphoma By Value
  3. Leukemia
    1. Leukemia By Value
  4. Myeloma
    1. Myeloma By Value
Brazil
1. By Commercialized Therapies
  1. Introduction
    1. Commercialized Therapies By Value
  2. Imlygic
    1. By Value
  3. Oncorine
    1. By Value
  4. RIGVIR
    1. By Value
2. By Pipeline Therapies
  1. Introduction
    1. Pipeline Therapies By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
3. By Type of Virus
  1. Introduction
    1. Type of Virus By Value
  2. Genetically Engineered Oncolytic Virus
    1. By Value
    2. Herpes Simplex Virus (HSV)
      1. Herpes Simplex Virus (HSV) By Value
    3. Adenovirus
      1. Adenovirus By Value
    4. Vaccinia Virus
      1. Vaccinia Virus By Value
    5. Oncolytic Wild-Type Virus
      1. Oncolytic Wild-Type Virus By Value
  3. Reovirus (Respiratory Enteric Orphan Virus)
    1. By Value
    2. Newcastle Disease Virus (NDV)
      1. Newcastle Disease Virus (NDV) By Value
    3. Vesicolar Stomatitis Virus (VSV)
      1. Vesicolar Stomatitis Virus (VSV) By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Solid Tumor
    1. By Value
    2. Breast Cancer
      1. Breast Cancer By Value
    3. Prostate Cancer
      1. Prostate Cancer By Value
    4. Lung Cancer
      1. Lung Cancer By Value
    5. Glioblastoma
      1. Glioblastoma By Value
    6. Melanoma
      1. Melanoma By Value
    7. Other Applications
      1. Other Applications By Value
  3. Hematological Malignancies
    1. By Value
    2. Lymphoma
      1. Lymphoma By Value
    3. Leukemia
      1. Leukemia By Value
    4. Myeloma
      1. Myeloma By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Oncolytic Virus Therapies Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Amgen Inc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
DAIICHI SANKYO COMPANY LIMITED
DNAtrix
Genelux
Oncolytics Biotech Inc
PsiOxus Therapeutics
RIGVIR Ltd
Shanghai Sunway Biotech Co. Ltd.
SillaJen Inc
Sorrento Therapeutics Inc
Takara Bio Inc
Transgene SA
VCNBiosciences
ViroCure
Viralytics Ltd.(Merck & Co., Inc.)

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment